Our website is under construction
StemPrintER and SPARE
- Superior assay based on a stemness signature genes for early prediction of ER+/HER2‐ recurrence of breast cancer
- A side‐by‐side comparison study showed StemPrintER assay outperforms Oncotype DX assay by 40% in analysis with 800+ samples from ER+/HER2- postmenopausal breast cancer patients
- Second generation ‘SPARE’ Model is 40-50% more accurate than standard clinical markers in analysis with 1800+ samples for prediction of distant metastasis
StemPrintER is a multi-gene prognostic assay intended for the prediction of breast cancer recurrence in estrogen receptor-positive HER2-negative patients, based on the detection of 20 cancer stem cell markers. The assay has been evaluated in a retrospective validation study of approximately 2,400 breast cancer patients. Multigene prognostic tests can assist decision making on treatments, differentiating low risk patients who could be spared chemotherapy from higher risk patients who might benefit from chemotherapy.
Two posters were selected for presentation at virtual ASCO 2020 Conference. Data demonstrating the superiority of StemPrintER versus the market leader, Oncotype DX, was presented at the virtual ASCO 2020 conference.
A second generation StemPrintER model (SPARE) with refined accuracy of distant recurrence was also presented at the ASCO 2020 meeting.
It is expected that the Accustem Shares will have a standard listing on the Official List and be admitted to trading on the London Stock Exchange. A process is underway to seek admission to the standard segment of the Official List and trading on the London Stock Exchange. It is expected that Accustem Admission will occur during Q1, 2021.
Accustem American Depositary Shares’s (“ADSs”) will be distributed to the eligible holders of Tiziana ADS’s promptly after the Registration Statements described here are declared effective by the U.S. Securities and Exchange Commission (the “Commission”). During the remainder of 2020, Tiziana will proceed to file a registration statement for the new Accustem ordinary shares with the Commission and Accustem will establish a sponsored ADR program with JPMorgan. Accustem and JPMorgan will subsequently file a Form F-6 registration statement with the Commission in order to enable holders of Tiziana ADSs at the close of business (NY time) on the ADS Record Date to receive one ADS, each representing two ordinary shares of Accustem (CUSIP to be determined), for each Tiziana ADS held of record at such time.